According to The Insight Partners’ research, the global preterm birth control market is slated to amass US$ US$ 1,809.0 million by 2025 from US$ 1,190.5 million in 2017, expanding at 4.9% CAGR from 2018 to 2025. Increasing number of preterm births and initiatives to prevent preterm births are the key factors contributing to market expansion.

Based on treatment method, the global preterm birth control market is divided into pharmaceutical treatment and devices. Among these, the pharmaceutical treatment segment accounted for 55.6% of the market share in 2017. The segment was evaluated at US$ 661.9 million in 2017 and is anticipated to reach US$ 1,041.9 million by 2025, growing at 6.1% CAGR during the forecast period.

Regionally speaking, North America held a significant share in the global preterm birth control market in 2017. The regional market was assessed at US$ 448.1 million in 2017 and is estimated to garner US$ 718.2 million by 2025, expanding at a stellar growth rate of 6.3% between 2017 and 2025.

Leading players formulating the competitive landscape of the global preterm birth control market are CooperSurgical, Inc.; MedGyn Products, Inc.; Integra LifeSciences Corporation; Panpac Medical Corporation; Dr. Arabin GmbH & Co. KG; AMAG Pharmaceuticals, Inc.; Ben Way Enterprises Sdn. Bhd.; Personal Medical Corporation; Bioteque America, Inc.; and Bliss GVS Pharma Limited.

·         In April 2018, CooperSurgical Inc. acquired the assets of The LifeGlobal Group and its affiliates. The LifeGlobal Group is a leading global provider of in-vitro fertilization devices.

·         In February 2018, AMAG Pharmaceuticals received FDA approval for Makena (hydroxyprogesterone caproate injection) Subcutaneous Auto-Injector to reduce the risk of preterm birth in certain at-risk women. The prefilled Makena auto-injector offers a new administration option for patients and providers and contains a shorter, thinner non-visible needle compared to the intramuscular (IM) Makena injection. The breakthrough launch is expected to help AMAG Pharmaceuticals hold a prominent position in the global preterm birth control market.